Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology

The global oncology market is rapidly shifting toward smarter drug-delivery systems that enhance efficacy, reduce toxicity ...
The Malaysian Reserve

TREMFYA® (guselkumab), the first and only IL-23 inhibitor with a fully subcutaneous treatment regimen, demonstrates durable remission in Crohn’s disease at two years

Clinical remission rates were over 85% for both TREMFYA® maintenance doses at 96 weeks in both the Phase 3 GRAVITI and GALAXI studies TREMFYA® is the only ...